Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Clinical trial NCT03379727 · COMPLETED
Trial details
- NCT number
- NCT03379727
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-13
- Primary completion
- 2021-07-09
- Enrollment
- 301
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.